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Background: Ovarian cancer is frequently lethal despite aggressive multimodal therapy, and new
therapies are therefore needed. Retinoids are potential candidate drugs: they prevent the develop-
ment of ovarian carcinoma and enhance the efficacy of cytotoxic drugs in ovarian cancer cells. At
present, little is known about the retinoid receptor expression in ovarian cancer.
Patients and methods: The retinoid receptors comprise two classes, retinoic acid receptors (RARs)
and retinoid X receptors (RXRs), each with three subclasses, a, b and g. We investigated the
expression of the subtypes RARa, RARg, RXRa and RXRb by immunohistochemistry in ovarian
cancers of 80 patients, and assessed their prognostic significance. In addition, we quantified the
expression of retinoid receptor mRNA using real-time PCR and correlated the results with clinical
characteristics.
Results: RARa and RXRb were highly expressed in a majority of ovarian cancers, particularly in
advanced stages. High expression of RARa was an independent negative prognostic factor of survi-
val in addition to FIGO stage, age and p53 accumulation. The mRNA expression of retinoid recep-
tors did not correlate with clinical properties of the tumors.
Conclusions: Retinoic acid receptors are frequently and strongly expressed in epithelial ovarian can-
cer and may be indicators of an adverse prognosis. This study provides the molecular basis for the
therapeutic use of retinoids in ovarian cancer.
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Introduction
Ovarian cancer has the highest mortality rate among
malignancies of the female genital tract and is the fifth leading
cause of cancer death in women in the USA [1]. In
Switzerland, the incidence and mortality is comparable to
other Western countries [2]. By the time of diagnosis, most
patients have advanced stages of disease. Despite multimodal
therapy, 60% to 85% of these patients will die from recurrent
cancer [3]. Therefore, ongoing research focuses on the devel-
opment of more potent therapies.
Retinoids are potential candidates for new treatment strat-
egies for ovarian cancer. Retinoids are natural and synthetic
derivatives of retinol (vitamin A). The naturally occuring reti-
noids, all-trans retinoic acid, 9-cis retinoic acid and 13-cis reti-
noic acid, are generated from diet-derived retinol. Retinoids are
ligands of cellular receptors of retinoic acid, including retinoic
acid receptors (RARs) and retinoid X receptors (RXRs,
rexinoid receptors) [4]. These are members of the steroid and
thyroid hormone receptor superfamily [5]. Each subtype of
both retinoid receptor classes (RARa, RARb, RARg, and
RXRa, RXRb, RXRg, respectively) is encoded by separate
genes. Multiple isoforms of receptor subtypes exist as a result
of alternate splicing. The receptors act mainly as RAR–RXR
heterodimers, bind to specific DNA sequences (retinoic acid
response elements) and act as ligand-dependent transcription
factors [6].
The physiological functions of retinoids include the control
of proliferation, apoptosis and differentiation in normal cells
during growth and development [6]. Retinoids are essential in
the maintenance of normal adult epithelial differentiation.
Vitamin A-deficient experimental animals have long been
known to develop squamous metaplasia and other precancer-
ous lesions. These alterations were reversed by vitamin A
repletion [7]. Several subsequent studies demonstrated the
effect of retinoids in the chemoprevention of certain malignant
tumors [1, 8, 9]. Indeed, high dietary intake of carotenoids,
which are precursors of the physiologic retinoids, had a mod-
erate protective effect against ovarian cancer [10–14]. The
same effect was observed in a clinical trial evaluating the
effect of the atypical retinoid fenretinide on the prevention of
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contralateral breast cancer [15]. Surprisingly, none of the
patients in the treatment group developed ovarian cancer
during the intervention period. This benefit was lost when the
drug was discontinued, suggesting an effect of fenretinide
against ovarian cancer. [16]. The growth inhibitory effect of
retinoids has also been extensively studied in established ovar-
ian carcinoma cell lines [17]. Several in vitro studies revealed
that numerous mechanisms are involved such as induction of
apoptosis by various mechanisms [6, 18–20], interference
with cell cycle control [21] and cross-talk with other signaling
molecules such as AP1 [22] and epithelial growth factor [23].
Retinoids enhance the effect of cytotoxic drugs, such as cis-
platin [24–26] and docetaxel [27], and of ionizing radiation
[28] in ovarian cancer cell lines. The toxic effects of retinoids
differ from those of traditional cytotoxic agents. Thus, reti-
noids are potentially attractive partners for combination thera-
pies with cytotoxic drugs. Certain retinoids are in clinical use,
such as all-trans retinoic acid in the treatment of acute pro-
myelocytic leukemia [29] and targretin in the therapy of
cutaneous T-cell lymphoma [30], but their clinical application
for the therapy of solid tumors such as ovarian cancer is still
experimental.
Despite the knowledge of the biological effects of retinoids
in ovarian cancer, limited information is available on the
expression of retinoid receptors in these tumors [31]. There-
fore, the aim of the present study was to determine the
expression of RARa, RARg, RXRa and RXRb in paraffin-
embedded ovarian cancer tissues using immunohistochemistry,
and to measure the mRNA expression of all RAR and RXR
subtypes in frozen tissue samples with real-time quantitative
PCR.
Patients and methods
Tissue samples
Two tissue banks of ovarian tumors were used: between 1984 and 1996,
172 patients were treated at the University Hospital of Berne for malig-
nant tumors of the ovaries. One hundred and forty-five of these patients
had invasive epithelial ovarian adenocarcinoma and were included in a
previous study [32]. Of 80 of these patients, paraffin-embedded tissue
obtained from surgical resection specimens was available for immuno-
histochemical analysis after review of the slides by one of the authors
(M.K.). All tumors were classified and graded according to standard
WHO criteria [33]. Frozen samples from 35 ovarian adenocarcinomas and
adenomas were collected in 1999 at operating theatres of the University
Hospital of Berne, Switzerland. Tumor samples were selected by the
surgeon and by a postdoctoral fellow of our laboratory to exclude macro-
scopically identifiable non-tumor tissue. The tissue was snap-frozen in
liquid nitrogen in the operating theatre and stored at 708C until further
processing.
Patient data
Patient information was collected from clinical records after obtaining the
permission of the local ethics committee according to Swiss law; the
patient information was immediately anonymized. All 80 patients included
in the immunohistochemical study had undergone cytoreductive surgery.
Patient ages ranged from 18 to 82 years (median 57.5). Forty-seven
patients (59%) had serous carcinoma, 15 (18%) had mucinous carcinoma
and 13 (16%) had endometrioid adenocarcinoma. Two patients (2%) were
diagnosed with a clear cell carcinoma and three (4%) had unclassified car-
cinomas. Sixty-six of 80 patients had grade 2 or 3 carcinomas. The
majority of the patients had FIGO stage III/IV disease at the time of diag-
nosis (40 of 80 stage III, 21 of 80 stage IV).
Patients included in the real-time PCR (RT–PCR) analysis had under-
gone resection of a tumorous lesion of the ovary. Patient ages ranged
from 41 to 83 years (median 61). Thirteen patients (37%) had ovarian ade-
nomas and 22 (63%) had epithelial ovarian adenocarcinoma. Twenty-one
of 22 carcinomas (96%) were grade 2 or 3. Seventeen of 22 patients had
FIGO stage III/IV disease (10 stage III, seven stage IV). The main charac-
teristics of both patient sets are summarized in Table 1.
Immunohistochemistry
Tissues were prepared according to standard procedures including steps of
dewaxing, rehydration and pretreatment by boiling in a pressure cooker
(10 mM citrate buffer, pH 6.0), by boiling in a microwave oven (citrate
buffer; 100 mM Tris–5% urea, pH 9.5), or by digestion with 1 mg/ml
trypsin. The bound antibodies were visualized with biotinylated secondary
antibodies (DakoCytomation, Glostrup, Denmark) in conjunction with
streptavidin–biotin complex/horseradish peroxidase (Vector, Burlingame,
CA, USA) and developed in 0.1% 3,3-diaminobenzidine (Sigma, St Louis,
MO, USA) with 0.03% H2O2. The sections were counterstained with
hematoxylin. Positive controls were stained in parallel with each series.
They included human skin and breast tissue for the retinoic acid receptors,
tonsil for bcl-2, bax and MIB-1, and colon cancer for p53 and vimentin.
The monoclonal antibodies used included clone Vim3B4 for vimentin,
DO-7 for p53, 124 for bcl-2, MIB-1 for Ki-67 (all from DakoCytomation),
336* for RARb, 147 for RXRb and 1373* for RXRg (Neomarkers,
Fremont, CA, USA); polyclonal antibodies were used for bax (DakoCyto-
mation): RARa, RARb*, RARg, RXRa, RXRb* and RXRg* (all from
Table 1. Patient characteristics
Paraffin Frozen
n % n %
Number of patients 80 35
Age at diagonisis <50 years 23 29 11 31
51–65 years 29 36 10 29
>65 years 28 35 14 40
Histologya Carcinomas 80 100 22 63
Adenomas 0 0 13 37
Serous 48 60 11 50
Mucinous 14 18 2 9
Endometrioid 13 16 2 9
Clear cell 2 3 1 5
NOS 3 4 6 27
Histological gradea 1 8 10 1 5
2 19 24 5 23
3 53 66 16 73
FIGO stagea I&II 19 24 3 14
III 40 50 10 45
IV 21 26 7 32
aCarcinomas only.
NOS of otherwise specified.
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Santa Cruz, CA, USA). Antibodies marked with an asterisk showed no
reactivity when tested on various samples of formalin-fixed, paraffin-
embedded tissues and were therefore not used for the study.
The expression of all antigens except p53, Ki-67 and bax was
scored semiquantitatively by a modified histoscore method [34, 35].
The proportion score (0, <_ 5%; 1, <_ 30%; 2, <_50%; 3, <_70%; 4, <_95%; 5,
>95%) was added to the intensity score (1, weak; 2, intermediate; 3,
strong). Accumulation of abnormal p53 protein was defined as nuclear
staining in >10% of tumor cells [36]. For Ki-67, a proportion score was
used (0, <5%; 1, <10%; 2, <40%; 3, >40%) [37]. Bax was considered
positive if the intensity score was 2 [38]. Vimentin was used to assess the
quality of the tissue sections [39]. Each slide was evaluated independently
by two observers (P.C.K. and M.K.); divergences were resolved using a
double microscope.
cDNA synthesis and RT–PCR
Thirty milligrams of frozen tumor tissue was disrupted with a mortar and
pestle with concurrent cooling with liquid nitrogen. Total RNA was
extracted using the RNeasy Mini kit (Qiagen, Basel, Switzerland) accord-
ing to the manufacturer’s instructions. cDNA was synthesized from 1mg
total RNA in 25 ml reaction buffer using MMLV reverse transcriptase,
recombinant RNasin (Promega, Wallisellen, Switzerland) and random pri-
mers p(dN)6 (Roche, Rotkreuz, Switzerland) after DNase digestion with
DNase I (Roche, Rotkreuz, Switzerland). The cDNA products were used
for RT–PCR in a reaction mixture (25ml) containing 12.5ml 2SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and
forward and reverse primer at 300 nM. The primers for RARa, RARb,
RARg and RXRa, RXRb, RXRg were designed according to the NCBI
reference sequences for the corresponding genes (Table 2). 7S rRNA was
used as reference target sequence (primers: 50-accaccaggttgcctaagga and
50-cacgggagttttgacctgct). We used the ABI PRISM 7700 Sequence Detec-
tion System for RT–PCR. The following parameters were for used the
RT–PCR: initial denaturation (10 min at 958C) followed by 45 amplifica-
tion cycles (denaturation for 30 s at 958C, annealing for 30 s at 558C and
elongation for 15 s at 728C). We excluded the formation of primer dimers
by final melting curve analysis after RT–PCR (temperature slope 0.058C/s
from 40 to 1008C). All samples were measured as duplicates with a no-
template control in each run. PCR products of each primer pair were
cloned into plasmids using the TOPO TA Cloning Reaction (Invitrogen,
Basel, Switzerland) and calibration curves for each resulting plasmid were
established using 10-fold serial dilutions in 50mg/ml yeast RNA (Ambion,
Huntingdon, UK). The concentration of 7S was used as a control for RNA
content and for normalization of RNA content of each sample.
Statistical analysis
Group comparisons were based on Pearson’s x2-test for nominal and on
the linear x2-test for ordinal variables [40]. Correlations were evaluated
with the Spearman rank correlation coefficient. The RT–PCR data were
analyzed with non-parametric tests as the distributions of the retinoid
receptor: 7S ratios were highly skewed; the Mann–Whitney U statistic
was used for nominal and the Jonckheere–Terpstra test for intrinsically
ordered grouping variables. Survival was analyzed by Kaplan–Meier plots
[41] and proportional hazards regression [42]. The significant covariates
of the univariate analyses were used for the multivariate analysis;
log-minus-log plots did not reveal a violation of the proportionality
assumption. The patients were dichotomized by histoscore such that
approximately half were below and half above the cut-off value. In
addition, we performed the same analyses with age and histoscore as con-
tinuous variables; the results were virtually identical (not shown). The glo-
bal model significance was based on the x2 method and the significance of
individual covariates on the Wald statistic. Two-sided tests were used
throughout. All statistical analyses were performed using SPSS 11.5
(SPSS Inc., Chicago, IL, USA).
Results
Immunohistochemical study
Nuclear expression of RARa, RARg, RXRa and RXRb was
present in carcinoma cells (Figure 1). Specific immunore-
activity for RARb and RXRg was not discernible, either in a
selection of ovarian cancers or in other tissues that were sup-
posed to express the antigen. No mRNA for RXRg was
detected in frozen ovarian cancer tissue in contrast to mRNA
for RARb. The expression of RARa, RARg, RXRa and
RXRb is summarized in Table 3.
Table 2. Real time PCR primers sequences for RARa, RARb, RARg and RXRa, RXRb, RXRg
Gene Reference
sequence no.
Orientation Sequence Positions Product size (hp)
RARa NM_000964 Forward 50-cagagcagcagttctgaagagata 292–315 184
Reverse 50-gacacgtgtacaccatgttcttct 452–475
RARb NM_000965 Forward 50-gtcaccgagataagaactgtgtta 819–812 179
Reverse 50-actcagctgtcatttcatagctctc 937–997
RARg NM_000966 Forward 50-ctgtatcatcaacaaggtgacca 822–844 183
Reverse 50-tggtgatgagctcttctaactgag 980–1003
RXRa NM_002957 Forward 50-tgcttcgtgtaagcaagtacataag 4699–4723 192
Reverse 50-ctctttatggatctgtcatcctctc 4866–4890
RXRb NM_021976 Forward 50-ccagagtctctttttacacttcacc 2293–2317 182
Reverse 50-tcttagtcaacctgggaaagtacag 2450–2474
RXRg NM_006917 Forward 50-gatctagaggcagattcctgactaa 6–30 187
Reverse 50-catgtttactcgtcagttcatgttc 167–191
RAR, retinoid acid receptor; RXR, retinoid X receptor.
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RARa was expressed in the majority of the tissue sections,
and 48 patients (60%) had a high score of 7 or 8. High
RARa expression was significantly related to advanced
FIGO stages (P= 0.04). The expression of RARg was similar
in different histological types of ovarian carcinoma. Tumors
with lower FIGO stages had lower levels of RARg. RXRa
was highly expressed in most of the tissue samples; in 36
patients (45%) a score of 7 to 8 was observed. There were
no significant correlations of RXRa expression with clinical
or morphological features. RXRb was strongly expressed in
the majority of the tumors, with 70% scoring 7 to 8. Low
FIGO stage tumors showed a trend towards lower expression
levels. There was no significant relation between RXRb
expression and other clinical or pathological features. Ki-67
and p53 were present in the nuclei, while bcl-2 and bax anti-
gens were distributed in the cytoplasm. Ki-67 was correlated
with tumor grade (P= 0.03), whereas the detection of p53
was not associated with clinical variables. The expression of
bcl-2 was low in the majority of the patients and was not
correlated with other variables. Bax showed a high
expression level in the majority of the tumors, and there was
a trend towards higher bax expression in low-grade tumors
(P = 0.07).
The expression of RARa and RXRa was positively corre-
lated (Spearman’s rank correlation coefficient 0.32; P= 0.004),
as was that of RARa and RXRb (correlation coefficient 0.26;
P= 0.02). RARg was not correlated with the evaluated anti-
gens. RXRa was also positively correlated with bax (corre-
lation coefficient 0.22; P= 0.04), as was RXRb with bcl-2
(correlation coefficient 0.27; P= 0.014). No correlation was
observed between markers of proliferation (Ki-67), p53 status
and apoptosis (bcl-2 and bax).
Survival data are summarized in Figure 2 and Table 4.
Patients with FIGO stage III and IV cancers had median survi-
val times of 52 and 14 months, respectively, whereas the
median survival was not reached in stage I and II cancers.
RARa and RARg were predictors of survival in univariate
proportional hazards regression analysis, in addition to age,
FIGO stage and p53 status. FIGO stage, p53 status and RARa
expression were independent predictors of survival: high
expression of RARa indicated a higher risk of death from
ovarian cancer.
Figure 1. Immunohistochemical staining of retinoid receptors in epithelial ovarian cancer. HE, hematoxylin and eosin; RAR, retinoic acid receptor; RXR,
retinoid X receptor.
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Table 3. Expression of retinoid receptor, ki-67, p53, bcl-2 and bax
All patients Age class Histology Grade Stage
<50 51–65 >65 Serous Mucinous Endometroid Unclassified Clear cell 1 2 3 FIGO 1&2 FIGO 3 FIGO 4
23 29 28 48 14 13 1 2 8 19 53 19 40 21
Immunohistochemistry score
RAR a
1–3 1 (4%) 2 (7%) 0 1 (2%) 1 (8%) 0 0 1 (50%) 1 (14%) 0 2 (4%) 2 (11%) 0 1 (5%)
4–6 9 (39%) 13 (45%) 6 (22%) 19 (40%) 5 (38%) 3 (23%) 0 1 (50%) 5 (71%) 7 (37%) 16 (30%) 10 (53%) 11 (28%) 7 (33%)
7–8 13 (57%) 14 (48%) 21 (78%) 28 (58%) 7 (54%) 10 (77%) 2 (100%) 0 1 (14%) 12 (63%) 35 (66%) 7 (37%) 28 (72%) 13 (62%)
P* 0.11 0.13 0.047 0.036
RAR g
1–3 13 (57%) 10 (34%) 12 (43%) 15 (31%) 9 (64%) 8 (62%) 1 (50%) 2 (100%) 4 (50%) 11 (58%) 20 (38%) 13 (68%) 17 (43%) 5 (24%)
4–6 8 (35%) 15 (52%) 13 (46%) 25 (52%) 5 (36%) 4 (31%) 1 (50%) 0 4 (50%) 7 (37%) 25 (47%) 5 (26%) 16 (40%) 15 (71%)
7–8 2 (9%) 4 (14%) 3 (11%) 8 (17%) 0 1 (8%) 0 0 0 1 (5%) 8 (15%) 1 (5%) 7 (18%) 1 (5%)
P* 0.47 0.16 0.11 0.030
RXR a
1–3 6 (26%) 11 (38%) 7 (25%) 17 (25%) 2 (14%) 4 (31%) 0 1 (50%) 3 (38%) 5 (26%) 16 (30%) 4 (21%) 11 (28%) 9 (43%)
4–6 9 (39%) 4 (14%) 7 (25%) 11 (23%) 3 (21%) 4 (31%) 1 (50%) 1 (50%) 1 (13%) 3 (16%) 16 (30%) 6 (32%) 11 (28%) 3 (14%)
7–8 8 (35%) 14 (48%) 14 (50%) 20 (42%) 9 (64%) 5 (38%) 1 (50%) 0 4 (50%) 11 (58%) 21 (40%) 9 (47%) 18 (45%) 9 (43%)
P* 0.52 0.56 0.63 0.40
RXR b
1–3 2 (9%) 1 (3%) 1 (4%) 2 (4%) 1 (7%) 1 (8%) 0 0 1 (13%) 1 (15%) 2 (4%) 1 (5%) 2 (5%) 1 (5%)
4–6 7 (30%) 7 (24%) 7 (25%) 10 (21%) 5 (36%) 4 (31%) 1 (50%) 1 (50%) 3 (38%) 4 (21%) 14 (26%) 9 (47%) 9 (23%) 3 (14%)
7–8 14 (61%) 21 (72%) 20 (71%) 36 (75%) 8 (57%) 8 (62%) 1 (50%) 1 (50%) 4 (50%) 14 (74%) 37 (70%) 9 (47%) 29 (73%) 17 (81%)
P* 0.40 0.70 0.39 0.060
Ki-67
<5% 10 (48%) 15 (52%) 17 (63%) 28 (60%) 8 (67%) 4 (31%) 1 (50%) 0 6 (100%) 12 (63%) 24 (46%) 10 (59%) 18 (46%) 14 (67%)
5–10% 2 (10%) 6 (21%) 4 (15%) 8 (17%) 2 (17%) 1 (8%) 0 1 (50%) 0 3 (16%) 9 (17%) 2 (12%) 6 (15%) 4 (21%)
11–40% 6 (29%) 6 (21%) 6 (22%) 7 (15% ) 2 (17%) 7 (54%) 1 (50%) 1 (50%) 0 2 (11%) 16 (31%) 2 (12%) 13 (33%) 3 (14%)
>40% 3 (14%) 2 (7%) 0 4 (9%) 0 1 (8%) 0 0 0 2 (11%) 3 (6%) 3 (18%) 2 (5%) 0
P* 0.10 0.18 0.030 0.34
p53
Negative 5 (22%) 2 (7%) 11 (41%) 10 (22%) 4 (29%) 2 (17%) 2 (100%) 0 3 (38%) 0 15 (29%) 3 (16%) 11 (28%) 4 (21%)
Positive 18 (78%) 25 (93%) 16 (59%) 36 (78%) 10 (71%) 10 (83%) 0 2 (100%) 5 (63%) 18 (100%) 36 (71%) 16 (84%) 28 (72%) 15 (79%)
P* 0.10 0.40 0.56 0.62
1
4
8
1
RNA expression study
The results of mRNA quantitation of the major classes of
retinoid receptors are summarized in Table 5. All types of
receptors were expressed in ovarian adenomas and carcinomas
except for RXRg. We did not observe significant associations
between the mRNA expression of retinoid receptors and clini-
cal features.
Discussion
The present study is the first to systematically investigate the
expression of retinoid receptors in epithelial ovarian cancer
tissue. We demonstrate that retinoid receptors are highly
expressed in a large proportion of ovarian cancers, and that
high expression of RARa independently predicts an unfavor-
able prognosis in addition to established prognostic factors
such as stage and age. The population in this study comprised
all patients treated at our institution between 1984 and 1996
for whom tissues blocks were available. Although no stan-
dardization of the measurement, assessment and reporting of
retinoid receptors exists, the methodology used in the present
study is in accordance with usual procedures for the quanti-
tation and reporting of nuclear hormone receptors by immuno-
histochemistry [34].
Despite substantial improvement of the surgical and medi-
cal therapy, ovarian cancer continues to be a highly lethal dis-
ease. Even with state-of-the-art surgery and modern
chemotherapy, the probability of long-term survival is  30%
for the majority of patients with stage III and IV disease
[43–45].
Retinoids have numerous biological effects: depending on
the cellular context, they induce differentiation, inhibit the cel-
lular proliferation or cause apoptosis [46]. All-trans retinoic
acid was one of the first examples of ‘targeted’ therapy: it
induces remissions in a majority of patients with promyelocy-
tic leukemia. Moreover, retinoids prevent the development of
solid tumors [47] including ovarian carcinoma [15], and pre-
liminary data indicate that retinoids are also effective in the
therapy of certain solid tumors. In a recently reported phase II
trial, fenretinide was shown to be active in ovarian cancer
[48]. Retinoids interact in vitro with conventional cytotoxic
drugs such as cisplatin [24–26] and the taxanes paclitaxel and
docetaxel [27, 49, 50] to lower the threshold of apoptosis. The
clinical side-effects of retinoids do not overlap with the typical
toxicity of cytotoxic chemotherapeutic agents. Thus, clinical
and in vitro evidence make retinoids attractive investigational
agents for the combination with conventional cytotoxic
chemotherapy.
Most biological effects of retinoids are mediated through
retinoid receptors; previous work has established that retinoid
receptors are expressed in a variety of ovarian cancer cell lines.
However, the expression of retinoid receptors has hardly been
investigated in clinical ovarian cancer tissues. In the present
study we observed that the retinoid receptors RARa, RARg,
RXRa and RXRb were present in a majority of ovarian cancer
tissues, especially in advanced-stage tumors and those withT
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poor differentiation. It is thus not surprising that the high
expression of RARa was a negative prognostic factor of survi-
val. The lack of apparent correlation between the expression of
mRNA and protein by immunohistochemistry may be
explained by the impossibility of cross-calibration of antibody
binding affinity and by the unavailability of a suitable antibody
for RARb. Similar observations were made in oral squamous
cell carcinoma, where RARa was an independent indicator of a
poor prognosis [51]. RARa was correlated with unfavorable
prognostic factors such as high grade and high proliferation
rate in prostate [52] and breast [53] cancer. Considering the
role of retinoids in normal epithelial cell differentiation, the
biological mechanisms underlying this observation are not
obvious. At least two potential explanations have been pro-
posed. (i) In human cell systems including MCF7 breast cancer
cells, retinoic acid enhances the ubiquitylation of RARa and
induces its degradation in the proteasome [54, 55]. Thus, in
conditions of low concentrations of retinoic acid at the recep-
tor, the degradation of RARa might be inhibited; alternatively,
the post-transcriptional regulation of RARa could be deranged
by an unknown mechanism. (ii) Unliganded RARa molecules
may inhibit the retinoic acid-dependent processes such as
differentiation [56] and apoptosis, perhaps by inhibiting the
effects of RARb; the expression of the latter is induced by
liganded RARa and is lost as an early event in the carcinogen-
esis of various tumors [57].
The presence of RXRs, although not of independent prog-
nostic value in this study, may also be important: RXRs are
obligatory dimerization partners for other members of the
steroid receptor superfamily such as other retinoid receptor
subtypes, the thyroid hormone receptor, the peroxisome pro-
liferator-activated receptor gamma (PPARg) and the vitamin
D receptor. PPARg has very recently been shown to be
expressed in ovarian cancer and may play a role in the
development of epithelial ovarian carcinoma [58]. Thus, the
expression of retinoic acid receptors may be a predictive
marker for the therapeutic utility of retinoids and PPARg
ligands similar to the current use of estrogen receptor
assessment for the prediction of endocrine responsiveness in
breast cancer. Given the complexity of the retinoid signaling
pathways it appears likely that retinoid receptors are
required though not sufficient to predict the action of reti-
noids. For instance, the expression of RARb predicted the
response to isotretinoin (13-cis retinoic acid) in a proportion
of patients with renal cell cancer [59]. Moreover, the RXR
agonist bexarotene is active in about one-fifth of patients
with metastatic breast cancer; unfortunately, it has not been
investigated whether the expression of RXR is correlated
Figure 2. Overall survival by FIGO stage, age, p53 immunohistochemistry and retinoic acid receptor a (RARa) immunohistochemistry score.
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with the responsiveness to bexarotene [60]. In ovarian can-
cer, fenretinide induced a clinically worthwhile benefit in a
minority of patients with ovarian cancer, even though the
patients were not selected for retinoid receptor expression
[48]. It is conceivable that with a more selective use of reti-
noids exclusively in tumors that express retinoic acid recep-
tors, a substantially better benefit to toxicity ratio may be
achieved in combination with conventional chemotherapy.
Although the present investigation is limited by the
small number of samples analyzed and the virtual lack of
information on RARb protein, it reveals that certain retinoid
receptors are present in human epithelial ovarian cancer.
RARa may be associated with an adverse prognosis indepen-
dently of established prognosticators such as FIGO stage. This
finding will have to be verified in a larger independent set of
tumor samples. The present study provides the molecular
basis for clinical trials to evaluate the efficacy of retinoids in
ovarian cancer; this prospect is promising in view of preclini-
cal data that show a synergic interaction with platinum drugs
and taxanes.
Table 4. Prognostic factors of survival
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Age years 0.015 0.81
<50 Reference Reference
50–65 2.02 (0.86–4.8) 1.35 (0.50–3.6
65 + 3.52 (1.49–8.3) 1.32 (0.49–3.5)
Grade 0.26
1 Reference Reference
2 3.36 (0.73–15.4)
3 3.24 (0.77–13.6)
FIGO stage <0.001 <0.001
I/III Reference Reference
III 3.48 (1.02–11.8) 2.02 (0.56–7.3)
IV 12.0 (3.55–40.9) 13.1 (3.4–50)
Immunohistochemistry
p53 0.04 0.050
Negative Reference Reference
Positive 0.47 (0.23–0.97) 0.41 (0.17–1.00)
Ki-67 (score) 0.96 (0.72–1.27) 0.35
Bcl-2 (score) 0.98 (0.84–1.13) 0.75
Bax 0.82
Negative Reference
Positive 0.92 (0.48–1.80)
RAR a 0.002 0.003
Score 1–6 Reference Reference
Score 7–8 2.99 (1.49–6.03) 3.77 (1.56–9.1)
RAR g 0.02 0.95
Score 1–4 Reference Reference
Score 5–8 2.15 (1.12–4.12) 0.975 (0.42–2.3)
RXR a 0.26
Score 1–5 Reference
Score 6–8 1.45 (0.76–2.79)
RXR b 0.10
Score 1–6 Reference
Score 7–8 1.91 (0.88–4.17)
CI. confidence interval, RAR, retinoid acid receptor; RXR, retinoid X receptor.
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Table 5. mRNA expression of retinoid receptors (copies of retinoid receptor mRNA/copies of 7S rRNA)
RAR a RAR b RAR g RXR a RXR b RXR g
Median 25–75 percentile Pa Median 25–75 percentile Pa Median 25–75 percentile Pa Median 25–75 percentile Pa Median 25–75 percentile Pa
All patients 0.007 0.003–0.014 0.188 0.04–0.287 0.048 0.023–0.121 0.259 0.1–0.479 0.177 0.023–0.314
Not detected 2 3 0 3 4 31
Age (years) <50 0.013 0.006–0.021 0.06 0.194 0.071–0.287 0.75 0.083 0.031–0.168 0.14 0.374 0.242–0.543 0.24 0.246 0.015–0.333 0.40
51–65 0.007 0.003–0.036 0.177 0.094–0.221 0.049 0.039–0.173 0.308 0.21–0.518 0.196 0.096–0.265
>65 0.006 0–0.009 0.225 0.034–0.348 0.038 0.023–0.107 0.265 0.096–0.366 0.157 0.025–0.431
Histology Adenoma 0.007 0.002–0.009 0.22 0.223 0.066–0.291 0.65 0.045 0.038–0.057 0.17 0.335 0.142–0.516 0.82 0.165 0.35–0.222 0.18
Carcinoma 0.008 0.003–0.017 0.180 0.41–0.322 0.100 0.018–0.20. 0.255 0.12–0.519 0.240 0.064–0.431
Grade Borderline 0.015 0.22 0.002 0.21 0.018 0.48 0.015 0.95 0.01 0.66
Grade 1 0.08 0.083 0.031 0.243 0.200
Grade 2 0.013 0.05–0.025 0.172 0.014–0.863 0.130 0.601–0.404 0.382 0.169–1.127 0.333 0.148–0.756
Grade 3 0.011 0.004–0.015 0.194 0.167–0.287 0.168 0.032–0.246 0.251 0.15–0.511 0.392 0.0840–0.461
Unknown 0.004 0–0.016 0.360 0.34–0.684 0.073 0.017–0.205 0.238 0.142–0.693 0.146 0.062–0.376
Stage FIGO I&II 0.015 0.000–0.021 0.92 0.284 0.001–0.570 0.62 0.054 0.11–0.332 0.76 0.259 0.011–0.806 0.97 0.246 0.001–0.468 0.74
FIGO III 0.008 0.006–0.013 0.188 0.083–0.287 0.130 0.032–0.237 0.271 0.242–0.382 0.296 0.177–0.428
FIGO IV 0.007 0.003–0.025 0.110 0.023–0.863 0.049 0.013–0.404 0.217 0.095–1.127 0.114 0.041–0.709
aJonckheere–Terpstra test, except histology: Mann–Whitney U-test.
RAR, retinoic acid receptor; RXR retinoid X receptor.
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